TIL earnings analysis
What we found in TIL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Instil’s Q2 2026 results showed substantial year-over-year improvement, with the diluted loss narrowing to $0.63 per share from $3.24 and operating expenses falling to $5.6 million from $23.4 million. Liquidity of $69.9 million is expected to fund the operating plan beyond 2027, but the company remains loss-making and faces material Tarzana facility risks, including $58.4 million of cumulative impairment charges. The filing provided no numeric revenue or EPS guidance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- GAAP Loss Narrowed
- GAAP diluted loss narrowed to $0.63 per share in Q2 2026 from $3.24 per share in Q2 2025, an improvement of $2.61 per share.
- Operating Expenses Reduced
- Operating expenses declined to $5.6 million from $23.4 million in the year-ago quarter, a reduction of $17.8 million, or approximately 76%.
- Liquidity Supports Plan Beyond 2027
- Liquidity totaled $69.9 million at June 30, 2026, which management expects to fund the operating plan beyond 2027.
- Controls Remained Effective
- Management reported that disclosure controls and procedures were effective as of June 30, 2026, and that there were no material changes in internal control during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Tarzana Facility Impairment Risk
- The company has recorded $58.4 million of impairment charges on long-lived assets related to its Tarzana, California facility, including a charge in Q2 2026, and may incur additional impairment losses.
- Facility Sale May Not Cover Debt
- If the Tarzana facility is sold, the company may not recover its carrying value or sell it for an amount equal to or greater than the secured debt encumbering the facility; the filing cites $58.4 million of cumulative impairment charges.
- Continued Losses Consume Liquidity
- Liquidity was $69.9 million at June 30, 2026, and the company continues to report significant losses despite the Q2 2026 diluted loss improving to $0.63 per share from $3.24 per share in Q2 2025.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.63
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management stated that $69.9 million of cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026 is expected to fund the operating plan beyond 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 15, 2026
- Instil Bio reported a significantly improved EPS of -$0.97 in Q4 2026, compared to both an EPS estimate of -$3.19 and a prior loss of -$1.17 in Q4 2025, driven by decreased operating expenses. However, the company…
- 10-K · March 27, 2026
- Instil Bio (TIL) announced in the filing that it discontinued development of its former lead candidate AXN-2510 and terminated the ImmuneOnco license in January 2026, and the company now states it has no product…
- 10-Q · November 13, 2025
- Instil Bio reported a narrower GAAP loss in Q3 2025 with net loss per share improving to $(2.01) from $(3.54) a year earlier and consolidated net loss shrinking to $13,587k from $23,021k. Results were driven by…
- 10-K · March 4, 2025
- Instil Bio is a clinical-stage biopharma focused on a bispecific PD-L1xVEGF antibody (AXN-2510/IMM2510) and in-licensing additional assets; in August 2024 its subsidiary Axion Bio in-licensed AXN-2510 and AXN-27M from…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TIL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever